Anticipatory and consummatory effects of (hedonic) chocolate intake are associated with increased circulating levels of the orexigenic peptide ghrelin and endocannabinoids in obese adults

References

• Egecioglu E, Skibicka KP, Hansson C, Alvarez-Crespo M, Friberg PA, Jerlhag E, etal. Hedonic and incentive signals for body weight control. Rev Endocr Metab Disord. 2011; 12: 141–51.
   Google Scholar
• Yeomans MR, Blundell JE, Leshem M. Palatability: response to nutritional need or need-free stimulation of appetite?. Br J Nutr. 2004; 92: S3–14.
   Google Scholar
• Zheng H, Berthoud HR. Neural systems controlling the drive to eat: mind versus metabolism. Physiology. 2008; 23: 75–83.
   Google Scholar
• Finlayson G, King N, Blundell JE. Liking vs. wanting food: importance for human appetite control and weight regulation. Neurosci Biobehav Rev. 2007; 31: 987–1002.
   Google Scholar
• Lutter M, Nestler EJ. Homeostatic and hedonic signals interact in the regulation of food intake. J Nutr. 2009; 139: 629–32.
   Google Scholar
• Rui L. Brain regulation of energy balance and body weight. Rev Endocr Metab Disord. 2013; 14: 387–407.
   Google Scholar
• Jerlhag E, Egecioglu E, Dickson SL, Douhan A, Svensson L, Engel JA. Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens. Addict Biol. 2007; 12: 6–16.
   Google Scholar
• Dickson SL, Egecioglu E, Landgren S, Skibicka KP, Engel JA, Jerlhag E. The role of the central ghrelin system in reward from food and chemical drugs. Mol Cell Endocrinol. 2011; 340: 80–7.
   Google Scholar
• Di Marzo V, Ligresti A, Cristino L. The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Int J Obes. 2009; 33: S18–24.
   Web of Science ®Google Scholar
• Cristino L, Becker T, Di Marzo V. Endocannabinoids and energy homeostasis: an update. Biofactors. 2014; 40: 389–97.
   Google Scholar
• Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology. 2005; 30: 1216–21.
   Google Scholar
• Monteleone P, Piscitelli F, Scognamiglio P, Monteleone AM, Canestrelli B, Di Marzo V, etal. Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. J Clin Endocrinol Metab. 2012; 97: E917–24.
   Google Scholar
• di Tomaso E, Beltramo M, Piomelli D. Brain cannabinoids in chocolate. Nature. 1996; 382: 677–8.
   Google Scholar
• Di Marzo V, Sepe N, De Petrocellis L, Berger A, Crozier G, Fride E, etal. Trick or treat from food endocannabinoids?. Nature. 1998; 396: 636–7.
   Google Scholar
• Garner DM, Olmsted MP, Bohr Y, Garfinkel PE. The eating attitudes test: psychometric features and clinical correlates. Psychol Med. 1982; 12: 871–8.
   Google Scholar
• Annuzzi G, Piscitelli F, Di Marino L, Patti L, Giacco R, Costabile G, etal. Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis. 2010; 9: 43.
   Google Scholar
• Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001; 50: 707–9.
   PubMed Web of Science ®Google Scholar
• English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab. 2002; 87: 2984.
   Google Scholar
• Simonian HP, Kresge KM, Boden GH, Parkman HP. Differential effects of sham feeding and meal ingestion on ghrelin and pancreatic polypeptide levels: evidence for vagal efferent stimulation mediating ghrelin release. Neurogastroenterol Motil. 2005; 17: 348–54.
   Google Scholar
• Malik S, McGlone F, Bedrossian D, Dagher A. Ghrelin modulates brain activity in areas that control appetitive behaviour. Cell Metab. 2008; 7: 400–9.
   Google Scholar
• Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?. Brain Res Rev. 1998; 28: 309–69.
   Google Scholar
• Karra E, O'Daly OG, Choudhury AI, Yousseif A, Millership S, Neary MT, etal. A link between FTO, ghrelin, and impaired brain food-cue responsivity. J Clin Invest. 2013; 123: 3539–51.
   Google Scholar
• De Silva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner EA, etal. The gut hormones PYY 3-36 and GLP-1 7-36amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab. 2011; 14: 700–6.
   Google Scholar
• Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, etal. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003; 349: 941–8.
   Google Scholar
• Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, etal. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord. 1999; 23: 304–11.
   PubMed Web of Science ®Google Scholar
• Horvath TL, Castañeda T, Tang-Christensen M, Pagotto U, Tschöp MH. Ghrelin as a potential anti-obesity target. Curr Pharm Des. 2003; 9: 1383–95.
   Google Scholar
• Álvarez-Castro P, Pena L, Cordido F. Ghrelin in obesity, physiological and pharmacological considerations. Mini Rev Med Chem. 2013; 13: 541–52.
   PubMed Web of Science ®Google Scholar
• Jager G, Witkamp RF. The endocannabinoid system and appetite: relevance for food reward. Nutr Res Rev. 2014; 27: 172–85.
   Google Scholar
• Izzo AA, Piscitelli F, Capasso R, Aviello G, Romano B, Borrelli F, etal. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol. 2009; 158: 451–61.
   Google Scholar
• Di Patrizio NV, Astarita G, Schwartz G, Li X, Piomelli D. Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci USA. 2011; 108: 12904–8.
   Web of Science ®Google Scholar
• Di Marzo V. Endocannabinoids: an appetite for fat. Proc Natl Acad Sci USA. 2011; 108: 12567–8.
   Google Scholar
• Kola B, Farkas I, Christ-Crain M, Wittmann G, Lolli F, Amin F, etal. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One. 2008; 3: e1797.
   Google Scholar
• Cani PD, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr. 2004; 92: 757–61.
   Google Scholar
• Rigamonti AE, Giordani C, Bonomo SM, Cella SG, Müller EE. Early tolerance to the hypophagic effect of the cannabinoid receptor antagonist SR141716 does not impede blockade of an orexigenic stimulus. Eur J Pharmacol. 2006; 542: 116–20.
   Google Scholar
• Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S, etal. Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry. 2011; 69: 633–41.
   Google Scholar
• Di Marzo V, Verrijken A, Hakkarainen A, Petrosino S, Mertens I, Lundbom N, etal. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol. 2009; 161: 715–22.
   Google Scholar
• Valenti M, Viganò D, Casico MG, Rubino T, Steardo L, Parolaro D, etal. Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cell Mol Life Sci. 2004; 61: 945–50.
   Google Scholar
• Osman JL, Sobal J. Chocolate cravings in American and Spanish individuals: biological and cultural influences. Appetite. 2006; 47: 290–301.
   Google Scholar